Norman W. Lavy, M.D.
This content is PDF only. Please click on the PDF icon to access.
Dr. Sande has emphasized the importance of pursuing, through controlled clinical research, the optimal therapeutic regimens for a number of relatively specialized site-organism categories. Dr. Christensen noted that to satisfy current regulatory requirements in bringing new antibiotics to market, industry must repetitively evaluate the same indications, redeveloping essentially the same kinds of data, the same kinds of efficacy information. Dr. Crout confirmed that for antibiotics, as for all other drugs, the law and the regulations do require "substantial evidence," consisting of adequate and well-controlled studies, before approval and marketing.
By examining all aspects of this issue, is it possible that
Lavy NW. Development of Antibiotics. Ann Intern Med. ;89:864–865. doi: 10.7326/0003-4819-89-5-864_4
Download citation file:
Published: Ann Intern Med. 1978;89(5_Part_2):864-865.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use